Efficacy and Safety of Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy for RAS Mutant-type Locally Advanced Rectal Cancer
Prospectively Investigate the effectiveness and safety of neoadjuvant Bevacizumab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS mutant-type locally advanced rectal cancer
• A biopsy proven histological diagnosis of rectal adenocarcinoma；
• An ARMS-PCR proven KRAS, NRAS mutation, excluding BRAF mutation or microsatellite instablility-High;
• No intestinal obstruction, distant metastasis was excluded by CT, MRI or PET / CT;
• MRI proven T3c-T4, CRM positive, N2, extramural vascular invasion positive or lateral lymph node positive of locally advanced rectal cancer;
• Age between 18-75 years;
• ECOG (Eastern US Cooperative Oncology Group) score: 0-1;
• Has sufficient organ function:
‣ Hemopoietic function: hemoglobin ≥ 90 g / L, platelet ≥ 80 g / L × 109 / L,
⁃ neutrophils ≥ 1.5 × 109/L
⁃ Liver function: ALT and AST \< 2.5 × ULN;
⁃ Renal function: serum creatinine \< 1.5 ULN;
• Willing to participate and informed consent signed；